Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2006

View Archived Issues

Novel pathway involved in ADPKD identified / News in Context

New class of PG transporter inhibitors presented

Novel ligand-antibody protein specifically enhances cell lysis in MM

ViroPharma licenses right to develop novel therapeutic for CDAD

Zenyth enters licensing agreement with Ludwig Institute for Cancer Research

Oragenics: business plan for 2006

Callisto to study atiprimod in carcinoid cancer patients

Lucentis BLA for wet AMD granted priority review

Medivation updates progress of Dimebon for Alzheimer's and Huntington's disease

FDA accepts Genasense NDA for relapsed or refractory CLL

Invitrogen agreement supports DelSite's development of avian H5 flu nasal vaccine

RK-0202 set to enter phase III for oral mucositis

Treatment begins in phase III study of Delcath system

Pfizer acquires sanofi-aventis' rights to Exubera

Enzo cleared to begin HIV study of Stealth Vector HGTV43 gene construct

Albany Molecular Research completes acquisition of ComGenex

Astellas acquires Dynogen research facility

Novel compounds claimed for therapy of cardiovascular disorders in recent patent literature

Novel agents for treating diabetes and related complications disclosed in recent patents

BLA submission for Cimzia in Crohn's disease

FDA approval for Erbitux in head and neck cancer

sNDA seeks approval of Byetta for use with TZDs

Tygacil recommended for approval in Europe

Alcon withdraws European submission for Retaane

Tetracaine oral gel may be beneficial for relief of mucositis-related pain / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.